In summary, while we propose the combination of AFP and PIVKAII for HCC surveillance in NAFLD/ALD patients, the search for novel biomarkers of early HCC disease should continue. The gene discussed is AFP; the disease is metabolic dysfunction-associated steatotic liver disease.